Tuberc Respir Dis.  2013 Dec;75(6):236-237.

Overview of ALK and ROS1 Rearranged Lung Cancer

• Choi CM

Abstract

Many attempts have been made to find genetic abnormalities inducing carcinogenesis after the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor targeting EGFR in lung cancer. New target therapies have been already commercialized and studied along with the recent discovery of gene rearrangement involved in the carcinogenic process of non-small cell lung cancer. This study aims to investigate anplastic lymphoma kinase, c-ros oncogene 1, and receptor tyrosine kinase, in particular.

Keyword

Lung Neoplasms; Anplastic Lymphoma Kinase; ROS1 Protein, Human

MeSH Terms

Carcinogenesis
Carcinoma, Non-Small-Cell Lung
Gene Rearrangement
Lung Neoplasms*
Lung*
Lymphoma
Oncogenes
Phosphotransferases
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor
Phosphotransferases
Protein-Tyrosine Kinases
Receptor, Epidermal Growth Factor

Reference

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448:561–566. PMID: 17625570.

2. Doebele RC, Camidge DR. Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol. 2012; 7(16 Suppl 5):S375–S376. PMID: 23160323.

3. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer. 2012; 76:403–409. PMID: 22129856.

4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693–1703. PMID: 20979469.

5. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010; 363:1734–1739. PMID: 20979473.